Skip to main content
. Author manuscript; available in PMC: 2021 Aug 5.
Published in final edited form as: Mol Pharm. 2015 Jun 9;12(7):2544–2550. doi: 10.1021/acs.molpharmaceut.5b00257

Figure 2.

Figure 2.

In vitro cellular assays. Flow cytometry histograms showing binding of 38C2-3, 38C2-4, and 38C2-5 to (A) U87 glioblastoma, (B) Ln-CAP prostate cancer, and (C) MDA-MB-231 breast cancer cells. 38C2-5 has a stronger cell binding affinity than 38C2-3 and 38C2-4. The 38C2 Abs and FITC-labeled goat anti-mouse secondary Abs were used as negative controls. (D) ELISA histogram showing specific binding of 38C2-3, 38C2-4, and 38C2-5 to legumain and/or human integrin αvβ3 (*p < 0.001).